These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
197 related articles for article (PubMed ID: 27438197)
1. Infliximab in patients with psoriasis and other inflammatory diseases: evaluation of adverse events in the treatment of 168 patients. Antonio JR; Sanmiguel J; Cagnon GV; Augusto MS; Godoy MF; Pozetti EM An Bras Dermatol; 2016; 91(3):306-10. PubMed ID: 27438197 [TBL] [Abstract][Full Text] [Related]
3. Reasons for Discontinuation and Adverse Effects of TNFα Inhibitors in a Cohort of Patients With Rheumatoid Arthritis and Ankylosing Spondylitis. García-Lagunar MH; Gutiérrez-Cívicos MR; García-Simón MS; Conesa-Zamora P; Jimenez-Santos E; Cano-Vivar P; García-Márquez A; Muñoz-García I; Viney AC Ann Pharmacother; 2017 May; 51(5):388-393. PubMed ID: 27920336 [TBL] [Abstract][Full Text] [Related]
4. Stricturing and Fistulizing Crohn's Disease Is Associated with Anti-tumor Necrosis Factor-Induced Psoriasis in Patients with Inflammatory Bowel Disease. Weizman AV; Sharma R; Afzal NM; Xu W; Walsh S; Stempak JM; Nguyen GC; Croitoru K; Steinhart AH; Silverberg MS Dig Dis Sci; 2018 Sep; 63(9):2430-2438. PubMed ID: 29736839 [TBL] [Abstract][Full Text] [Related]
5. Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients. Wollina U; Hansel G; Koch A; Schönlebe J; Köstler E; Haroske G Am J Clin Dermatol; 2008; 9(1):1-14. PubMed ID: 18092839 [TBL] [Abstract][Full Text] [Related]
6. TNF-α inhibitor-induced psoriasis: A decade of experience at the Cleveland Clinic. Mazloom SE; Yan D; Hu JZ; Ya J; Husni ME; Warren CB; Fernandez AP J Am Acad Dermatol; 2020 Dec; 83(6):1590-1598. PubMed ID: 30576759 [TBL] [Abstract][Full Text] [Related]
7. Development of new-onset psoriasis in a patient receiving infliximab for treatment of rheumatoid arthritis. Chan CY; Browning JC; Larsen F; Hsu S Dermatol Online J; 2008 Sep; 14(9):12. PubMed ID: 19061594 [TBL] [Abstract][Full Text] [Related]
8. Paradoxical psoriasis after the use of anti-TNF in a patient with rheumatoid arthritis. Vasconcellos JB; Pereira DD; Vargas TJ; Levy RA; Pinheiro GD; Cursi ÍB An Bras Dermatol; 2016; 91(5 suppl 1):137-139. PubMed ID: 28300922 [TBL] [Abstract][Full Text] [Related]
9. Psoriasis induced by tumor necrosis factor-alpha antagonist therapy: a case series. Cohen JD; Bournerias I; Buffard V; Paufler A; Chevalier X; Bagot M; Claudepierre P J Rheumatol; 2007 Feb; 34(2):380-5. PubMed ID: 17013997 [TBL] [Abstract][Full Text] [Related]
10. [Tumour necrosis factor antagonists: infliximab, adalimumab and etanercept]. Breedveld FC Ned Tijdschr Geneeskd; 2005 Oct; 149(41):2273-7. PubMed ID: 16240851 [TBL] [Abstract][Full Text] [Related]
11. Therapeutic drug monitoring of infliximab compared to standard clinical treatment with infliximab: study protocol for a randomised, controlled, open, parallel-group, phase IV study (the NOR-DRUM study). Syversen SW; Goll GL; Jørgensen KK; Olsen IC; Sandanger Ø; Gehin JE; Warren DJ; Sexton J; Mørk C; Jahnsen J; Kvien TK; Bolstad N; Haavardsholm EA Trials; 2020 Jan; 21(1):13. PubMed ID: 31907007 [TBL] [Abstract][Full Text] [Related]
12. Should tumour necrosis factor antagonist safety information be applied from patients with rheumatoid arthritis to psoriasis? Rates of serious adverse events in the prospective rheumatoid arthritis BIOBADASER and psoriasis BIOBADADERM cohorts. García-Doval I; Hernández MV; Vanaclocha F; Sellas A; de la Cueva P; Montero D; Br J Dermatol; 2017 Mar; 176(3):643-649. PubMed ID: 27258623 [TBL] [Abstract][Full Text] [Related]
13. [Autoimmune aspects of treatment with TNF-alpha inhibitors]. Kolarz B; Targońska-Stepniak B; Darmochwał-Kolarz D; Majdan M Postepy Hig Med Dosw (Online); 2007 Aug; 61():478-84. PubMed ID: 17786135 [TBL] [Abstract][Full Text] [Related]
14. Acute and long-term effect of infliximab on humoral and echocardiographic parameters in patients with chronic inflammatory diseases. Tomáš L; Lazúrová I; Pundová L; Oetterová M; Zakuciová M; Petrášová D; Studenčan M Clin Rheumatol; 2013 Jan; 32(1):61-6. PubMed ID: 23010850 [TBL] [Abstract][Full Text] [Related]
15. Clinical pharmacokinetics and use of infliximab. Klotz U; Teml A; Schwab M Clin Pharmacokinet; 2007; 46(8):645-60. PubMed ID: 17655372 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of the safety and satisfaction of rheumatic patients with accelerated infliximab infusion. de Carvalho JF; Dos Santos MNP; de Oliveira JMV; Lanty Silva ANS; de Araujo RPC; Cardozo JB Adv Rheumatol; 2018 Aug; 58(1):22. PubMed ID: 30657070 [TBL] [Abstract][Full Text] [Related]
17. New indications for treatment of chronic inflammation by TNF-alpha blockade. Reimold AM Am J Med Sci; 2003 Feb; 325(2):75-92. PubMed ID: 12589232 [TBL] [Abstract][Full Text] [Related]
18. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital. Suwannalai P; Auethavekiat P; Udomsubpayakul U; Janvitayanujit S Int J Rheum Dis; 2009 Jul; 12(2):118-24. PubMed ID: 20374328 [TBL] [Abstract][Full Text] [Related]
19. TNF alpha inhibition as treatment modality for certain rheumatologic and gastrointestinal diseases. Wiedmann MW; Mössner J; Baerwald C; Pierer M Endocr Metab Immune Disord Drug Targets; 2009 Sep; 9(3):295-314. PubMed ID: 19594416 [TBL] [Abstract][Full Text] [Related]
20. Tumor necrosis factor α antagonist-associated psoriasis in inflammatory diseases: an analysis of the FDA adverse event reporting system. Kip KE; Swoger JM; Grandinetti LM; Barrie AM; Greer JB; Regueiro MD Inflamm Bowel Dis; 2013 May; 19(6):1164-72. PubMed ID: 23518804 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]